Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated:  7/25/2016
Children's Hospital of Michigan, Wayne State University
mi
from
Detroit, MI
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated: 7/25/2016
Children's Hospital of Michigan, Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated:  7/25/2016
New York University Langone Medical Center
mi
from
New York, NY
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated: 7/25/2016
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated:  7/25/2016
Cleveland Clinic Lerner College of Medicine
mi
from
Cleveland, OH
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated: 7/25/2016
Cleveland Clinic Lerner College of Medicine
mi
from
Cleveland, OH
Click here to add this to my saved trials
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated:  7/25/2016
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated: 7/25/2016
Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated:  7/25/2016
University of Texas Southwestern
mi
from
Dallas, TX
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
A Randomized, Placebo-controlled, Double-masked Clinical Trial of Buspirone in the Treatment of 2- 6 Year Old Children With Autistic Disorder
Status: Enrolling
Updated: 7/25/2016
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated:  7/25/2016
Stanford University Medical Center
mi
from
Palo Alto, CA
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated:  7/25/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated:  7/25/2016
Seattle Children's Hospital
mi
from
Seattle, WA
DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma
Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study
Status: Enrolling
Updated: 7/25/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Test Lung Stretch Therapy (Hyperinsufflation) in Children With Collagen VI Muscular Dystrophy
Congenital Muscular Dystrophy (CMD) and the Feasibility of Hyperinsufflation Therapy to Slow Rate of Decline in Lung Volume
Status: Enrolling
Updated:  7/25/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Study to Test Lung Stretch Therapy (Hyperinsufflation) in Children With Collagen VI Muscular Dystrophy
Congenital Muscular Dystrophy (CMD) and the Feasibility of Hyperinsufflation Therapy to Slow Rate of Decline in Lung Volume
Status: Enrolling
Updated: 7/25/2016
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Test Lung Stretch Therapy (Hyperinsufflation) in Children With Collagen VI Muscular Dystrophy
Congenital Muscular Dystrophy (CMD) and the Feasibility of Hyperinsufflation Therapy to Slow Rate of Decline in Lung Volume
Status: Enrolling
Updated:  7/25/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
A Study to Test Lung Stretch Therapy (Hyperinsufflation) in Children With Collagen VI Muscular Dystrophy
Congenital Muscular Dystrophy (CMD) and the Feasibility of Hyperinsufflation Therapy to Slow Rate of Decline in Lung Volume
Status: Enrolling
Updated: 7/25/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities
Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities
Status: Enrolling
Updated:  7/25/2016
Nationwide Children's Hospital
mi
from
Columbus, OH
Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities
Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities
Status: Enrolling
Updated: 7/25/2016
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia
Status: Enrolling
Updated:  7/25/2016
CPC1
mi
from
West Palm Beach, FL
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia
Status: Enrolling
Updated: 7/25/2016
CPC1
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Long Beach, CA
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Norwalk, CT
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Norwalk, CT
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Clearwater, FL
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Plantation, FL
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Plantation, FL
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Idaho Falls, ID
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
North Chicago, IL
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
North Chicago, IL
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Baltimore, MD
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Boston, MA
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Columbia, MO
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
New York, NY
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Columbia, SC
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
San Antonio, TX
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated:  7/25/2016
mi
from
Vancouver,
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
LY333531 Treatment of Symptomatic Peripheral Neuropathy in Patients With Diabetes
Status: Enrolling
Updated: 7/25/2016
mi
from
Vancouver,
Click here to add this to my saved trials
Can Short Latency Afferent Inhibition Give us Clues to Better DYT 1 Dystonia Treatments?
Can Short Latency Afferent Inhibition Give us Clues to Better Dystonia Treatments?
Status: Enrolling
Updated:  7/26/2016
UF Center for Movement Disorders and Neurorestoration
mi
from
Gainesville, FL
Can Short Latency Afferent Inhibition Give us Clues to Better DYT 1 Dystonia Treatments?
Can Short Latency Afferent Inhibition Give us Clues to Better Dystonia Treatments?
Status: Enrolling
Updated: 7/26/2016
UF Center for Movement Disorders and Neurorestoration
mi
from
Gainesville, FL
Click here to add this to my saved trials
Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine
A Single Dose Pharmacokinetic Study of Topical and Rectal Quetiapine Compared to Oral Quetiapine in Healthy Adults
Status: Enrolling
Updated:  7/26/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine
A Single Dose Pharmacokinetic Study of Topical and Rectal Quetiapine Compared to Oral Quetiapine in Healthy Adults
Status: Enrolling
Updated: 7/26/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery
Estradiol for Neurocognitive Dysfunction After CABG
Status: Enrolling
Updated:  7/28/2016
Washington University
mi
from
St. Louis, MO
Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery
Estradiol for Neurocognitive Dysfunction After CABG
Status: Enrolling
Updated: 7/28/2016
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery
Aminocaproic Acid and Bleeding in Spinal Surgery
Status: Enrolling
Updated:  7/28/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery
Aminocaproic Acid and Bleeding in Spinal Surgery
Status: Enrolling
Updated: 7/28/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement
Status: Enrolling
Updated:  8/1/2016
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine
mi
from
Miami, FL
NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement
Status: Enrolling
Updated: 8/1/2016
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Los Ageles, CA
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Los Ageles, CA
Click here to add this to my saved trials
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
New Haven, CT
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Bronx, NY
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis
A Single Center Study to Collect Samples From SMA Patients for Biomarker Analysis
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Kalamazoo, MI
A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis
A Single Center Study to Collect Samples From SMA Patients for Biomarker Analysis
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis
A Single Center Study to Collect Samples From SMA Patients for Biomarker Analysis
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Salt Lake, UT
A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis
A Single Center Study to Collect Samples From SMA Patients for Biomarker Analysis
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Salt Lake, UT
Click here to add this to my saved trials
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated:  8/1/2016
1160.129.32338 Boehringer Ingelheim Investigational Site
mi
from
Jackson, TN
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated: 8/1/2016
1160.129.32338 Boehringer Ingelheim Investigational Site
mi
from
Jackson, TN
Click here to add this to my saved trials
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated:  8/1/2016
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated: 8/1/2016
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated:  8/1/2016
1160.129.32052 Boehringer Ingelheim Investigational Site
mi
from
Lansing, MI
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated: 8/1/2016
1160.129.32052 Boehringer Ingelheim Investigational Site
mi
from
Lansing, MI
Click here to add this to my saved trials
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated:  8/1/2016
1218.75.030 Boehringer Ingelheim Investigational Site
mi
from
Memphis, TN
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated: 8/1/2016
1218.75.030 Boehringer Ingelheim Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated:  8/1/2016
205.452.01338 Boehringer Ingelheim Investigational Site
mi
from
Wyomissing, PA
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated: 8/1/2016
205.452.01338 Boehringer Ingelheim Investigational Site
mi
from
Wyomissing, PA
Click here to add this to my saved trials
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated:  8/1/2016
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated: 8/1/2016
1199.15.10027 Boehringer Ingelheim Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated:  8/1/2016
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated: 8/1/2016
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated:  8/1/2016
1270.1.32001 Boehringer Ingelheim Investigational Site
mi
from
Bruxelles,
BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.
Status: Enrolling
Updated: 8/1/2016
1270.1.32001 Boehringer Ingelheim Investigational Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
The Impact of Autonomic Dysfunction on Liver-Related Symptoms in Non-Alcoholic Fatty Liver Disease and Their Relationship to Systemic Inflammation and Insulin Resistance
Status: Enrolling
Updated:  8/1/2016
Virginia Commonwealth University Health System
mi
from
Richmond, VA
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
The Impact of Autonomic Dysfunction on Liver-Related Symptoms in Non-Alcoholic Fatty Liver Disease and Their Relationship to Systemic Inflammation and Insulin Resistance
Status: Enrolling
Updated: 8/1/2016
Virginia Commonwealth University Health System
mi
from
Richmond, VA
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
St. Josephs Hospital and Medical Center - Barrow Neurology
mi
from
Phonix, AZ
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
St. Josephs Hospital and Medical Center - Barrow Neurology
mi
from
Phonix, AZ
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Jordan Research and Education Institute (REDI): Alta Bates Summit Medical Center
mi
from
Berkeley, CA
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Jordan Research and Education Institute (REDI): Alta Bates Summit Medical Center
mi
from
Berkeley, CA
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
University of Southern California- Keck School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
Newport Beach Clinical Research Associates, Inc.
mi
from
Newport Beach, CA
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
Newport Beach Clinical Research Associates, Inc.
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated:  8/3/2016
University of California-Davis
mi
from
Sacramento, CA
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Status: Enrolling
Updated: 8/3/2016
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials